Summit Therapeutics 3Q 2026: Net loss $208.4M, EPS $(0.26) — 10-Q Summary

What happened

Summit Therapeutics reported a third-quarter 2026 net loss of $208.4M, narrower than its $231.8M loss a year earlier, and diluted loss per share improved to $(0.26) from $(0.31). The company reported progress in cancer trials, including completed HARMONi-3 cohort enrollment, and expects research and development spending to rise.

Confirmed

Global impact / market context

The smaller quarterly loss and improved loss per share indicate reduced losses year over year, but Summit remains unprofitable. Rising research and development spending as trials advance could increase costs before any trial results support regulatory approval or commercial revenue.

Analyst inference

The article describes a clinical-stage company whose financial outlook depends on cancer-trial progress and spending. The FDA's stated need for a significant overall survival benefit links approval prospects to whether treatment helps patients live longer, not solely to other trial benefits.

Analyst inference

What to watch

1. Watch for further HARMONi-3 updates, especially overall survival results, because the FDA said a significant overall survival benefit is needed for approval. Analyst inference
2. Track research and development spending as trials advance; the company expects it to rise, which may widen losses if costs increase faster than revenue. Analyst inference
3. Follow enrollment and progress in HARMONi-GU1 and the kidney cancer study, alongside colorectal and lung trials, as described in the article. Analyst inference

Evidence

• Original source link unavailable